Status:
COMPLETED
A Study to Evaluate the Effect of Danoprevir/Ritonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy Volunteers
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Healthy Volunteer
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This single-arm, open-label, non-randomized study will evaluate the effect of danoprevir/ritonavir on the pharmacokinetics of escitalopram and S-demethylcitalopram in healthy volunteers. Healthy volun...
Eligibility Criteria
Inclusion
- Adult healthy volunteers, aged 18 to 55 years, inclusive
- Body mass index (BMI) 18.0 to 32.0 kg, inclusive
- Absence of evidence of any active or chronic disease
- Non-smokers
Exclusion
- Presence of any active or chronic disease
- Abnormal blood pressure
- Abnormal resting heart rate
- Abnormal ECG values
- History of any clinically significant cardiovascular or cerebrovascular disease
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01418274
Start Date
August 1 2011
End Date
September 1 2011
Last Update
November 2 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lenexa, Kansas, United States, 66219